Clinical trial No longer in our active list Phase 4 Interventional Ages 18 to 70

Examining adherence to immunosuppressive medications in new liver transplant patients

Official title: A Prospective, Multi-center, Open-labeled, Randomized Clinical Trial of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant Recipients to Compare QD Early Conversion and BID Tacrolimus Formulation.

Run by Chang Gung Memorial Hospital · NCT03216447 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing whether new liver transplant patients stick to taking their daily immunosuppressive medications better with a once-a-day pill compared to a twice-a-day pill.

More Liver Transplantation trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment150 (estimated)
SponsorChang Gung Memorial Hospital
Academic / other
Locations1 site (Taoyuan)
Trial IDNCT03216447 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are primary liver transplant recipients aged 20 to 70 who can understand and follow study procedures.

Probably not a fit

Patients who have received other organ transplants or have certain medical conditions, such as requiring dialysis or being HIV positive, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how well newly transplanted liver patients adhere to immunosuppressive medications, specifically comparing a once-daily formulation (Advagraf®) to a twice-daily formulation (Prograf). It is a prospective, multi-center, open-labeled, randomized clinical trial that will enroll participants in Taiwan. Patients will be randomized on postoperative day 15 to assess their adherence and convenience with the medication regimen. The study aims to improve patient outcomes by optimizing medication adherence in this population.

Why it matters

Potential benefit: If successful, this study could enhance medication adherence and improve health outcomes for liver transplant recipients.

How similar studies have gone: Other studies have shown that optimizing immunosuppressive medication regimens can improve adherence and outcomes, suggesting this approach has potential.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient has been fully informed and has signed an IRB approved informed consent form within 7 days (Day 7-13) prior to POD 15 and is willing and able to follow study procedure
* Patient is a primary liver transplant recipient
* Patient is 20 to 70 years of age
* Patient should be clearly conscious, fully understand and able to answer questionnaire

Exclusion Criteria:

* Patient has previously received or is receiving an organ transplant other than a liver.
* Patient currently requires dialysis
* Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
* Patient has received a liver transplant from a non-heart beating donor
* Patient who is HCV negative has received an HCV positive (HCV RNA by PCR or HCV antibody) donor liver
* Patient who is HbsAg negative has received an HbsAg positive (HBV DNA by PCR or HBV antibody) donor liver
* Patient has received a liver transplant from a decrease donor \> 70 years of age
* Patient has a current malignancy or a history of malignancy (within the past 5 years), except hepatocellular carcinoma within UCSF Criteria and basal or non-metastatic squamous cell carcinoma of skin that has been treated successfully.
* Patient is hemodynamically unstable on POD 15

Where it's running

  • Chang Gung Memorial Hospital
    Taoyuan, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.